


UNITED STATES DEPARTMENT OF COMMERCE

Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARK
Washington, D.C. 20231

APPLICATION NUMBER / FILING/RECEIPT DATE / FIRST NAMED APPLICANT / ATTORNEY DOCKET NO/TITLE



08731/98 SMITH

0242/0929

SUGARLAND, MICH 47371 MACNEAL & SEARS
2100 PENNSYLVANIA AVENUE NW
WASHINGTON DC 20037-0202

NOT ASSIGNED

DATE MAILED:

09/10/1998

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

- 1. This application fails to comply with the requirements of 37 CFR 1.821 - 1.825.
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
- 7. OTHER: _____

APPLICANT MUST PROVIDE:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing."
- An initial or substitute paper copy of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

FOR/QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE CONTACT:

- For Rules Interpretation, call (703) 308-1123.
- For CRF submission help, call (703) 308-4212.
- For Patentin software help, call (703) 308-6856.

RECEIVED
OCT 13 1998
GROUP 180

Customer Service Center
Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

#6
Attachment

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

CRAIG A. SMITH et al

Appln. No.: **09/144,502**

Group Art Unit: **1646**

Filed: **August 31, 1998**

Examiner: **Fitzgerald, D.**

For: **DNA ENCODING TUMOR NECROSIS
FACTOR- α AND - β RECEPTORS**

**STATEMENT IN SUPPORT OF SUBMISSION IN
ACCORDANCE WITH FORMER 37 C.F.R. §§ 1.821-1.825**

Assistant Commissioner
of Patents
Washington, D.C. 20231

Sir:

The following statement is provided to meet the requirements of Former 37 C.F.R. §§ 1.821-1.825.

I hereby state that the content of the computer readable copy of the Sequence Listing submitted in accordance with Former 37 C.F.R. §§ 1.821-1.825, respectively, is the same as the Sequence Listing filed simultaneously herewith.


The Examiner is requested to note that the Sequence Listing being filed herewith is submitted under Former 37 C.F.R. §§ 1.821-1.825, as the present application is a reissue application of U.S. Patent No. 5,712,155 which issued January 27, 1998, based on U.S. Patent Application No. 08/346,555, filed November 29, 1994, i.e., prior to the effective new rules dated of July 1, 1998 (see 63 Federal Register 29620).

STATEMENT IN SUPPORT OF SUBMISSION IN
ACCORDANCE WITH FORMER 37 C.F.R. §§ 1.821-1.825
U.S. Appln. No. 09/144,502

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge and that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of this application or any patent issuing thereon.

10/9/98

Date


Gordon Kit